Latest Conference Articles

Data presented at the 2009 International Conference on Alzheimer's Disease in show that combination therapy with the investigational drug dimebon (latrepiridine) and donepezil HCl tablets was well tolerated in patients with mild to moderate Alzheimer’s disease.

Wellstat Therapeutics has developed vistonuridine, the first viable prodrug of uridine, which is an orally administered agent that delivers approximately 8-fold more uridine as it is converted to uridine in the body than administration of uridine itself.

A new retrospective study shows that use of three widely prescribed selective serotinin reuptake inhibitors—Prozac, Paxil, and Zoloft—more than double the risk of breast cancer recurrence in women treated with tamoxifen.

As you can well imagine, a cancer diagnosis can lead to an incredible amount of distress, which may be amplified once a patient starts to undergo treatment and experience its related side effects.

Geralyn Lucas, a very spunky breast cancer survivor, gave an amazing key note address that kept the audience engaged with her humor.

In a striking case report, the stimulant modafinil was able to dramatically improve neurological functioning in an elderly woman suffering from bilateral thalamic infarction, a disorder that often is fatal.

Dr. Busis talks about the current health IT climate, AAN efforts to educate members about the use of health IT in practice, the recently passed HITECH Act, the importance of interoperability, future drivers of health IT adoption, and more.

The history of the neurologic examination, referral pattern among neurologists for neurointerventional procedures, Parkinson's disease on the Internet, and online learning are just a few of the many topics discussed during the Day 2 sessions at the AAN meeting.

Alternating mammography and MRI every 6 months appears to be the best way to detect cancer in high-risk women, an M.D. Anderson study found. This strategy can identify cancers not found by mammography alone, said Huong Le-Petross, MD, assistant professor, Diagnostic Radiology, who presented a retrospective pilot study at a poster session during the San Antonio Breast Cancer Symposium.

Researchers have released findings from a large retrospective study showing that women treated for early stage HER2-positive breast cancer tumors ≤ 1cm have a significantly greater risk of recurrence than women whose tumors are HER2-negative.

When physicians first realize they are being sued for malpractice, they feel %u201Cshame, anger, depression, a loss of control, and a crisis of confidence."

A study reveals a beneficial effect of tamoxifen on breast cancer recurrences at 10 and 15 years of follow-up in women with ductal carcinoma in situ (DCIS).

Updates to the NCCN Prostate Cancer Guidelines were presented by James L. Mohler, MD.